全文获取类型
收费全文 | 678篇 |
免费 | 44篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 41篇 |
妇产科学 | 12篇 |
基础医学 | 93篇 |
口腔科学 | 29篇 |
临床医学 | 46篇 |
内科学 | 123篇 |
皮肤病学 | 16篇 |
神经病学 | 15篇 |
特种医学 | 146篇 |
外国民族医学 | 1篇 |
外科学 | 43篇 |
综合类 | 50篇 |
预防医学 | 41篇 |
眼科学 | 5篇 |
药学 | 21篇 |
中国医学 | 4篇 |
肿瘤学 | 32篇 |
出版年
2021年 | 9篇 |
2020年 | 7篇 |
2019年 | 5篇 |
2018年 | 14篇 |
2017年 | 13篇 |
2016年 | 14篇 |
2015年 | 13篇 |
2014年 | 20篇 |
2013年 | 31篇 |
2012年 | 29篇 |
2011年 | 21篇 |
2010年 | 44篇 |
2009年 | 46篇 |
2008年 | 25篇 |
2007年 | 21篇 |
2006年 | 9篇 |
2005年 | 7篇 |
2004年 | 5篇 |
2003年 | 4篇 |
2002年 | 5篇 |
2001年 | 8篇 |
2000年 | 7篇 |
1999年 | 10篇 |
1998年 | 37篇 |
1997年 | 34篇 |
1996年 | 34篇 |
1995年 | 35篇 |
1994年 | 23篇 |
1993年 | 20篇 |
1992年 | 4篇 |
1991年 | 4篇 |
1990年 | 7篇 |
1989年 | 15篇 |
1988年 | 14篇 |
1987年 | 10篇 |
1986年 | 13篇 |
1985年 | 9篇 |
1984年 | 12篇 |
1983年 | 14篇 |
1982年 | 12篇 |
1981年 | 13篇 |
1980年 | 15篇 |
1979年 | 4篇 |
1978年 | 8篇 |
1977年 | 2篇 |
1976年 | 8篇 |
1975年 | 5篇 |
1955年 | 1篇 |
1950年 | 1篇 |
1949年 | 1篇 |
排序方式: 共有726条查询结果,搜索用时 15 毫秒
1.
2.
E MOLKE JENSEN K. A. THIESSEN AA. CHRISTENSEN 《Acta anaesthesiologica Scandinavica》1986,30(2):109-110
The effect of 4 mg oral naloxone on preoperative gastric volume and pH of gastric aspirate was studied in a double-blind, randomized study. Twenty patients received 10 ml of naloxone (4 mg) mixed with 10 ml of orange juice, and 20 patients received 10 ml of isotonic saline mixed with 10 ml of orange juice, 2 h before surgery. Gastric content was obtained immediately after intubation of the trachea. No significant difference in gastric volume and pH of gastric aspirate was found between the two groups. It is concluded that naloxone does not affect gastric emptying and gastric acid secretion to a degree great enough to protect against aspiration of gastric contents into the lungs. 相似文献
3.
4.
5.
6.
MGC Hendriks P Dogterom JT Ebels B Oosterhuis LR Geertsema T Hulot G Bianchetti and JHG Jonkman 《Fundamental & clinical pharmacology》1998,12(5):559-565
Summary— In the present study we have compared the steady state biopharmaceutic characteristics of four diltiazem once daily controlled release capsules: Mono-Tildiem LP 300® (300 mg), Adizem® XL (300 mg)1, Cardizem® (300 mg) and Dilacor® (240 mg). Sixteen healthy male volunteers (aged 22.9 ± 3.3 years, range 19–31 years) completed an open label, multiple oral dose, randomized, four-period crossover study without a washout period in between. The volunteers received each diltiazem formulation once daily for four days. Trough diltiazem and metabolites plasma concentrations were determined on days 3 and 4. The 24-h plasma concentration-time profiles were assessed after the dose on day 4 of each period. The following steady state pharmacokinetic parameters for diltiazem were calculated: the minimum plasma concentration (cmin), the maximum plasma concentration (cmax), the time to reach that concentration (tmax), the time interval during which the plasma concentration exceeds 50% of cmax (t50), the area under the plasma concentration-time curve (AUC72–96) and the peak-to-trough fluctuation (PTF). For the metabolites of diltiazem, N-mono-desmethyl-diltiazem (NDM) and desacetyldiltiazem (DAD), AUC72–96 (AUCNDM and AUCDAD) and the ratio metabolite/parent compound were calculated. Steady state was achieved on day 3. Except one, all controlled release formulations have satisfactory controlled release properties allowing once daily administration. However, significant (P < 0.05) differences were found between the pharmacokinetic characteristics which do not allow exchange of the various formulations. Concentrations well below 50 ng·mL-1 in the morning hours were observed for Dilacor® (240 mg) and Adizem® XL (300 mg), which could be a disadvantage of these formulations as it is well-known that ischaemic events occur at a higher rate during that part of the day. The plasma concentration profiles of NDM and DAD, the major circulating metabolites, parallel the plasma concentration profiles for the parent compound. From a clinical point of view, all treatments were well tolerated. 相似文献
7.
8.
9.
10.
Verkerke GJ Geertsema AA Mihaylov D Blanksma PK Rakhorst G 《The International journal of artificial organs》2000,23(11):765-773
The PUCA (pulsatile catheter) pump is a left ventricular assist device (LVAD) capable of unloading the left ventricle (LV) and improving coronary flow by providing a counterpulsation effect. It consists of an extracorporeal located membrane pump, coupled to a transarterial catheter that enters the body via a superficial artery and ends in the LV. Blood is aspirated from the LV and pumped in the ascending aorta through the same catheter guided by a valve system. Timing and frequency of the PUCA pump influence its efficacy. To study the influence of several pump parameters a numerical model of the device and the circulatory system has been developed. Results of animal experiments were used to validate the model. Optimization studies resulted in a pump configuration with a stroke volume of 50 cc and pump:heart frequency mode of 1:2 that starts ejection at the beginning of diastole. 相似文献